세계의 3가 독감 백신 시장 - 시장 규모 : 백신 유형별, 연령층별, 유통 채널별, 지역별, 예측

Trivalent Flu Vaccine Market Size And Forecast

Trivalent Flu Vaccine Market size was valued at USD 6.36 Billion in 2024 and is projected to reach USD 9.59 Billion by 2032, growing at a CAGR of 5.80% from 2026 to 2032.

Global Trivalent Flu Vaccine Market Drivers

The market drivers for the Trivalent Flu Vaccine Market can be influenced by various factors. These may include:

Influenza Strain Prevalence:The demand for the vaccination is directly impacted by the frequency and severity of influenza strains, especially those that are protected by the trivalent vaccine. Variations in vaccine composition and demand can be caused by changes in circulating strains.

Government Recommendations and Regulations:The market demand for flu vaccine products can be greatly impacted by government regulations and recommendations made by health authorities. Uptake rates of the flu vaccination can be increased via public health campaigns.

Healthcare Infrastructure and Awareness:Having access to healthcare services and being aware of the value of getting vaccinated against the flu are essential. Enhanced healthcare facilities and education initiatives can raise immunization rates, which will propel market expansion.

Seasonal changes and Epidemics:Flu vaccination demand may rise in response to seasonal changes in flu outbreaks as well as sporadic epidemics or pandemics. The demand for and awareness of flu vaccinations can also be influenced by events like the COVID-19 pandemic.

Technological Developments:By increasing vaccine efficacy, lowering production costs, and increasing supply capacity, developments in vaccine manufacturing technology, such as cell-based or recombinant vaccine production, can have an impact on the market.

Demographic Factors:The demand for vaccines can be influenced by factors such as age distribution and vulnerability to complications from the flu. Demand may be driven by high-risk demographics like the elderly, small children, and people with long-term medical issues.

Healthcare Costs and Insurance Coverage:The cost and availability of flu shots are influenced by healthcare costs and insurance coverage. Vaccination rates can rise as a result of expanded insurance coverage and reimbursement guidelines.

Competitive Landscape:The rivalry between pharmaceutical firms producing trivalent flu shots can have an impact on product innovation, pricing, and distribution routes.

Globalization and Travel:As a result of increased worldwide travel and globalization, influenza viruses are spreading around the world, increasing the need for flu vaccinations.

Global Trivalent Flu Vaccine Market Restraints

Several factors can act as restraints or challenges for the Trivalent Flu Vaccine Market. These may include:

Vaccine Efficacy: Depending on how closely the vaccine resembles the viral strains that are currently in circulation, the effectiveness of trivalent flu shots can differ. Inconsistencies between the vaccine and common strains might diminish effectiveness and erode public trust in immunization campaigns.

Vaccine Safety Concerns: People may be discouraged from getting vaccinated due to worries about the safety of the vaccine's ingredients or side effects, which could affect the market's uptake. Misinformation can affect people's perceptions of vaccine safety, which can result in vaccine hesitation.

Restricted Access to Healthcare Services: Distribution and administration of vaccines may be hampered by limited access to healthcare services, especially in rural or underserved areas. The uptake of vaccines may be hampered by obstacles like cost, transportation, and deficiencies in the healthcare system.

Competition from Other vaccinations:The market for trivalent vaccinations may be impacted by competition from other flu vaccine formulations, such as nasal spray or quadrivalent vaccines. To retain market share, manufacturers need to set their products apart and show that they are safer or more effective.

Regulatory Difficulties: Manufacturers must incur money and bear administrative difficulties in order to comply with regulations pertaining to vaccination licensing, manufacturing standards, and post-market surveillance. Market entry or expansion may be hampered by regulatory procedural delays or uncertainty.

Global Economic Situation: Recessions and downturns in the economy can have an impact on healthcare spending priorities, which can result in budgetary restrictions for immunization programs and a decline in the willingness of consumers to pay for vaccinations out of pocket.

Vaccine Hesitancy: Vaccine hesitancy can damage public confidence in flu vaccination and impede market expansion. It might be caused by disinformation, mistrust of healthcare authorities, or cultural views.

Disruptions in the vaccine supply chain, such as shortages of raw materials, problems during manufacturing, or difficulties with distribution, can result in shortages or delays in the supply, which can affect the accessibility and availability of the vaccine on the market.

Fatigue from Pandemic Preparedness: Even with heightened knowledge of the hazards posed by pandemics, apathy or fatigue with regard to influenza and vaccine campaigns might lessen the urgency of getting vaccinated against the flu, especially in times of low flu activity.

Global Trivalent Flu Vaccine Market Segmentation Analysis

The Global Trivalent Flu Vaccine Market is Segmented on the basis of Type of Vaccine, Age Group, Distribution Channel, and Geography.

Type of Vaccine:

Inactivated Influenza Vaccines (IIV): These vaccines contain killed influenza viruses and are administered via injection.

Live Attenuated Influenza Vaccines (LAIV): These vaccines contain weakened influenza viruses and are administered via nasal spray.

Recombinant Influenza Vaccines: These vaccines are produced by genetic engineering methods and do not require the use of flu virus.

Age Group:

Pediatric Vaccines: Designed for children, typically aged 6 months to 17 years.

Adult Vaccines: Targeted for individuals aged 18 to 64 years who do not fall into the pediatric or elderly categories.

Elderly Vaccines: Specifically formulated for individuals aged 65 years and above, who are at higher risk of flu-related complications.

Distribution Channel:

Hospitals and Clinics: Vaccines are distributed through healthcare facilities where they are administered by healthcare professionals.

Pharmacies: Vaccines are available for purchase and administration at retail pharmacies.

Public Health Programs: Distribution occurs through government-run vaccination campaigns and public health initiatives.

Geography:

North America: Market conditions and demand in the United States, Canada, and Mexico.

Europe: Analysis of the Trivalent Flu Vaccine Market in European countries.

Asia-Pacific: Focusing on countries like China, India, Japan, South Korea, and others.

Middle East and Africa: Examining market dynamics in the Middle East and African regions.

Latin America: Covering market trends and developments in countries across Latin America.

Key Players

Sanofi Pasteur

GlaxoSmithKline (GSK)

Seqirus

Merck & Co., Inc.

Pfizer Inc.

F. Hoffmann-La Roche Ltd.

CSL Limited

Mylan N.V.

AstraZeneca

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL TRIVALENT FLU VACCINE MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL TRIVALENT FLU VACCINE MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL TRIVALENT FLU VACCINE MARKET, BY TYPE OF VACCINE

• 5.1 Overview
• 5.2 Inactivated Influenza Vaccines (IIV)
• 5.3 Live Attenuated Influenza Vaccines (LAIV)
• 5.4 Recombinant Influenza Vaccines

6 GLOBAL TRIVALENT FLU VACCINE MARKET, BY AGE GROUP

• 6.1 Overview
• 6.2 Pediatric Vaccines
• 6.3 Adult Vaccines
• 6.4 Elderly Vaccines

7 GLOBAL TRIVALENT FLU VACCINE MARKET, BY DISTRIBUTION CHANNEL

• 7.1 Overview
• 7.2 Hospitals and Clinics
• 7.3 Pharmacies
• 7.4 Public Health Programs

8 GLOBAL TRIVALENT FLU VACCINE MARKET, BY GEOGRAPHY

• 8.1 Overview
• 8.2 North America
  • 8.2.1 U.S.
  • 8.2.2 Canada
  • 8.2.3 Mexico
• 8.3 Europe
  • 8.3.1 Germany
  • 8.3.2 U.K.
  • 8.3.3 France
  • 8.3.4 Rest of Europe
• 8.4 Asia Pacific
  • 8.4.1 China
  • 8.4.2 Japan
  • 8.4.3 India
  • 8.4.4 Rest of Asia Pacific
• 8.5 Rest of the World
  • 8.5.1 Latin America
  • 8.5.2 Middle East & Africa

9 GLOBAL TRIVALENT FLU VACCINE MARKET COMPETITIVE LANDSCAPE

• 9.1 Overview
• 9.2 Company Market Ranking
• 9.3 Key Development Strategies

10 COMPANY PROFILES

• 10.1 AstraZeneca
  • 10.1.1 Overview
  • 10.1.2 Financial Performance
  • 10.1.3 Product Outlook
  • 10.1.4 Key Developments
• 10.2 Sanofi S.A
  • 10.2.1 Overview
  • 10.2.2 Financial Performance
  • 10.2.3 Product Outlook
  • 10.2.4 Key Developments
• 10.3 Abbott
  • 10.3.1 Overview
  • 10.3.2 Financial Performance
  • 10.3.3 Product Outlook
  • 10.3.4 Key Developments
• 10.4 GlaxoSmithKline
  • 10.4.1 Overview
  • 10.4.2 Financial Performance
  • 10.4.3 Product Outlook
  • 10.4.4 Key Developments
• 10.5 Merck
  • 10.5.1 Overview
  • 10.5.2 Financial Performance
  • 10.5.3 Product Outlook
  • 10.5.4 Key Developments
• 10.6 Novartis
  • 10.6.1 Overview
  • 10.6.2 Financial Performance
  • 10.6.3 Product Outlook
  • 10.6.4 Key Developments
• 10.7 Pfizer
  • 10.7.1 Overview
  • 10.7.2 Financial Performance
  • 10.7.3 Product Outlook
  • 10.7.4 Key Developments
• 10.8 Johnson & Johnson
  • 10.8.1 Overview
  • 10.8.2 Financial Performance
  • 10.8.3 Product Outlook
  • 10.8.4 Key Developments
• 10.9 Serum Institute of India
  • 10.9.1 Overview
  • 10.9.2 Financial Performance
  • 10.9.3 Product Outlook
  • 10.9.4 Key Developments
• 10.10 CSL Limited
  • 10.10.1 Overview
  • 10.10.2 Financial Performance
  • 10.10.3 Product Outlook
  • 10.10.4 Key Developments

11 Appendix

• 11.1 Related Research